BIOMARK DIAGNOSTICS INC.

Form 51-102F1
Management's Discussion & Analysis
Quarterly Report
For the Quarter Ended June 30, 2019

1.1 Date of Report: August 28, 2019

The following management's discussion and analysis ("MD&A") should be read together with the condensed consolidated financial statements and accompanying notes for the quarter ended June 30, 2018, which are prepared in accordance with International Financial Reporting Standards ("IFRS"). All amounts are stated in Canadian dollars unless otherwise indicated.

This MD&A includes certain statements that may be deemed "forward-looking statements". Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "project", "predict", "potential", "could", "might", "should" and other similar expressions. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements.

1.2 Overall Performance

BioMark Diagnostics Inc. was incorporated under the Business Corporation Act of British Columbia on June 19, 2014. The head office of the Company is 165-10551 Shellbridge Way, Richmond, British Columbia, V6X 2W8.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions to help detect, monitor, and assess treatment for cancer early and cost effectively. The platform technology is also designed to be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information please visit the company website at: www.biomarkdiagnostics.com

Announcements and Highlights during the quarter:

- Management continues to raise capital through private placement, family funds and other strategic sources to support completion of clinical trials studies and commercialization of its core technology platform. Management has been working on numerous non-dilutive financing with various government institutions across Canada and USA.

- On April 16th, 2019, BioMark announced that it successfully closed the private placement as per new release on April 9th, 2019. The Issuer issued 2,000,000 units at a price of CAD $0.10 per unit for gross proceeds of $ 200,000. Each unit consists of one common share of the Issuer and one share purchase warrant.
- On April 17th, 2019, BioMark was pleased to announce that its application entitled "Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma", submitted to the Collaborative Health Research Projects funding opportunity, had been approved. The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). The funding is approximately for $750,000. BioMark is the industrial partner on the grant.
- The manuscript entitled "Predictive value and clinical significance of increased SSAT-1 activity in healthy adults", which was submitted to Future Science OA, has been accepted on April 24th, 2019. The manuscript will be available in PubMed in August 2019.
- On May 15th, 2019, the abstract titled "Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity" was published online and released by American Society for Clinical Oncology (ASCO) for the upcoming annual meeting scheduled from May 29th to June 4th, 2019 in Chicago.
- In late May 2019, BioMark team signed a LOI with the University of Maryland School of Medicine to collaborate in discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity following GBM resection. Both parties that involved principal investors discussed clinical trial design, scope of the study and timing. During the visit, BioMark team visited core labs to determine available analytical capabilities, accreditation/compliance and to assess the possibility for conducting longitudinal studies in the future. This activity was supported by Going Global Innovation Program offered by Global Affairs Canada with key objectives of developing and validating BioMark's robust markers with international partners.
- On May 30th, 2019, BioMark was pleased to announce that its patent titled "DETECTION AND QUANTIFICATION OF ACETYLAMANTADINE IN URINE SAMPLES" was recently granted in United States.
- BioMark and TMIC submitted to Alberta Cancer Foundation "Early Detection Comprehensive Program Plan "as requested for a final short-listed review. The total grant request is for $475,000 and a decision is anticipated by July/August 2019.

- On June 18th, 2019, BioMark announced that it has arranged a voluntary debt to share settlement with certain directors and officers of the Company in connection with existing indebtedness related to services provided to the Company by such directors and officers (and for which amounts had accrued as reflected in the Company's financial statements but which had not been paid). The company issued a total of 1,000,000 common shares at (the "Debt Shares") at a deemed price of $0.15 per Debt Share in settlement of the indebtedness in aggregate amount of $150,000. No warrants were issued in connection with the debt settlement. The Debt Shares will be subject to a four month plus 1-day hold period.
- On June 26th, 2019, BioMark announced that the Company confirmed the collaboration arrangement with University of Maryland School of Medicine to collaborate in discovery and validation of BioMark's assays for early lung cancer and monitoring of residual tumor load/activity following glioblastoma multiforme (GBM) resection.
- Discovery paper in the use of new metabolites in conjunction with Amantadine assay to increase tissue specificity has been completed and the plan is to submit the manuscript to a peer reviewed journal in mid July 2019. A team of authors from both Canada and USA were involved in the publication.
- Posters were presented at the Canadian Society of Pharmacology and Therapeutics meeting in Calgary June 12-14 by Dr. Don Miller and two of his PhD students. These posters provided further proof our SSAT activity and link to acetyl amantadine discovery and potential pharmaceutical application in knock down of SSAT for glioblastoma during radio and chemotherapy.
- New patents were filed in June related to discovery and validation of early lung cancer biomarkers.
- Additional patients for the response to treatment study for lung cancer following chemo and radiation treatment were recruited at CancerCare Manitoba. A halfway analysis of the study might be conducted to determine potential success or adjustment to the clinical protocol.

Collaborative Health Research Project (CHRP)

Collaborative Health Research Projects (CHRP) is a joint initiative between the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Social Sciences and Humanities Research Council of Canada (SSHRC). CHRP grants support focused, interdisciplinary, collaborative research projects involving any field of the natural sciences or engineering and any field of the health sciences.

Proposed research projects should be innovative, with a strong focus on knowledge translation, and lead to health benefits for Canadians, more effective health services and/or economic development in health-related areas.

About Going Global Innovation Program

The Going Global Innovation (GGI) program is specifically designed to promote and enhance Canada's international innovation efforts. The program supports researchers who aim to commercialize technology by pursuing collaborative international research and development (R&D) opportunities through partnerships with key players in foreign markets.

Risk Factors and Uncertainty

The Company is focused on more select market introduction and development of all its product lines while instituting cost control of product development. The failure to generate future sales in the Company's main products could have a significant and adverse affect on the Company.

The Company is engaged in conducting additional clinical research related to technology positioning and regulatory submissions. Negative clinical trials along with regulatory non-approval or delays could adversely affect sales, product commercialization and could have a major impact on the Company. Additionally, industry evolution and existing or new market entrants can impact the competitive position of BioMark. New detection and screening technologies in genomics, epigenetics, exosomes, and liquid biopsy incorporating big data can negatively impact BioMark commercialization efforts.

BioMark's success will depend in large measure on certain key personnel. The loss of the services of such key personnel could have a material adverse affect on the Company. The contributions of these individuals to the immediate operations of BioMark are of central importance. In addition, there can be no assurance that BioMark will be able to continue to attract and retain all personnel necessary for the development and operation of its business.

Management is continuing efforts to attract additional equity and capital investors and implement cost control measures to maintain adequate levels of working capital. Nevertheless, there can be no assurance provided with respect to the successful outcome of these ongoing actions. If the Company is unable to obtain additional financing on reasonable terms, the Company may be required to curtail or reduce its operations to continue as a going concern.

In addition, the Company's limited working capital could affect the Company's ability to seize upon opportunities requiring investment, or to reinvest in its products in a timely manner.

1.3 Selected Quarter Information

The following information is a summary of the current quarter and year-to-date results including a comparison of financial performance to the corresponding previous year. The information is presented on the same basis as the consolidated financial statements and should be read in conjunction with the statements and accompanying notes.

	June 30, 2019	March 31, 2019	June 30, 2018
	$	$	$
Total Expenses	120,557	545,612	110,911
Net Loss	120,557	545,612	110,911
Loss Per share	0.00	0.01	0.00
Total Assets	174,662	34,642	149,893
Distribution or Cash Dividends	None	None	None

For discussion of annual information refer to sections 1.4 and 1.5.

1.4 Discussion of Operations

The Company generated no revenues for the quarter ended June 30, 2019 and has recorded a net loss of $120,557. The net loss slightly increased by $9,646 compared to the previous year of $110,911. This was due to increased research costs and professional fees. Total assets increased to $174,662 for the quarter ended June 30, 2019 compared to $34,642 reported on March 31, 2019. This capital increase is attributed to Share Subscription received for the exercise of warrants by existing shareholders.

Consulting service fees remains the same as the previous year. Professional fees and filing and transfer agent fees increased by $3,488 and $1,412 respectively compared to the same period of last year due to growing business and capital raise activities. The Share-based compensation was $nil compared to $1,068 reported on June 30, 2018. The Company currently has no reported payroll and engages on the basis of consulting services as needed.

Travel expenses during the period was $1,498 compared to $6,163 for the previous year, the decrease of $4,665 was a result of government funding to balance out some travel costs related to the trip to US. The office and miscellaneous remained at similar levels due to the existing rental agreement and prudent operating cost.

Research and other expense increased by $ 10,667 due to the cost of ongoing response to treatment clinical trial at CancerCare Manitoba. The Company is expecting to increase investment spending associated with research, sample and data analysis, regulatory submission, potential point of care test kit, incorporation of AI /imaging, presentations and publications in the next quarter.

Upcoming Potential Operational Objectives

In the coming quarters, BioMark will continue to evolve its business operations to help further leverage its expertise in cancer detection, monitoring and assessment. Some key business objectives initiatives include:

- Actively raise capital especially with institutional, family funds and strategic investors

- Submit and respond to questions related to its application to Health Canada for diagnostic application of its SSAT1 initially using LCMS. The LCMS is the industry gold reference standard, hence to gain recognition the company is focusing on this analytical methodology; See notes below on activities related to our clinical trials.

- Revalidate and advance the clinical commercialization of its customized fingerprint assay with The Metabolomics Innovation Centre (TMIC) and authorized lab service company for lung cancer. A larger cohort of samples with an emphasis on earlier stage lung cancer samples along with appropriate controls is currently being sourced through registered bio depository centre in Quebec and other centres across N. America and re-analyzed/revalidated at accredited partner labs after the initial analysis and prototype kits are optimized at TMIC. In addition, the company will enhance its supporting software as needed for the assay through services rendered at leading Machine learning institute. The company anticipates the completion of the sample validation by end of this fiscal year provided finances are raised.

- Continue to research and develop better quantification technologies or methods that will enhance the signal detection and reduce overall costs associated with sample collection and preparation. The company's goal is to lower cost detection costs associated with our platform; Elisa tests using BioMark's monoclonal antibodies are currently being conducted which will be compared to our LCMS test for accuracy and reproducibility. Successful outcome will provide avenues to introduce the tests in centres that require economic and fast turnaround times (doctor offices for example).

- Conduct and appropriately register the clinical trials which include measuring response to radiation and chemotherapy and surgical intervention firstly for lung cancer and then for glioblastoma; A first readout on lung cancer response to treatment pilot test is anticipated in by the end of December 2019.

- Develop stronger industry collaborations both locally and internationally with leading institutions and clinicians

- Publish in leading journals and highlight our breakthroughs at important meetings and symposiums

- Seek strong industrial local and international partners to engage in co-development projects

- Apply for appropriate government grants with partner institutions in Canada and USA

- Continues to build the operating and scientific team

1.5 Summary of Quarterly Results

The following information is a summary of the Company's financial results for the eight most recently completed quarters.

	June 30, 2019	March 31, 2019	December 31, 2018	September 30, 2018
	$	$	$	$
Total Revenue	-	-	-	-
Expenses	120,557	105,475	168,668	160,558
Net Loss	(120,557)	(105,475)	(168,668)	(160,558)
Loss per Share	(0.00)	(0.00)	(0.00)	(0.00)

	June 30, 2018	March 31, 2018	December 31, 2017	September 30, 2017
	$	$	$	$
Total Revenue	-	-	-	-
Expenses	110,911	147,536	176,375	218,422
Net Loss	(110,911)	(147,536)	(176,375)	(218,422)
Loss per Share	(0.00)	(0.00)	(0.00)	(0.00)

1.6 Liquidity

The Company has total assets of $174,662 as at June 30, 2019 consisting of cash and amounts receivable and has a negative working capital of $892,931.

At June 30, 2019, the Company had cash and cash equivalents of $155,154 (June 30, 2018 – $130,679) and working capital deficit increased by $43,122 from June 30, 2018 ($849,809) due to the increase of liabilities during the year. Working capital is defined as current assets less current liabilities. Total liabilities increased by $67,891 from June 30, 2018 ($998,062) which is mainly due to the increase of Due to related parties that accumulated during the years. Cash and cash equivalents decreased by $24,475 and is attributed to the cash obtained from warrants exercise by existing share holders.

Cash utilized in operating activities during the quarter ended June 30, 2019 shows a decrease in items not affecting cash which includes shares issued for debt settlement in conjunction to related party dues. (Note 5 in the Interim Financial Statement)

At June 30, 2019, share capital was $4,717,368 comprising 69,145,410 issued and outstanding common Shares (June 30, 2018 – $4,086,774 comprising 62,794,119 issued and outstanding common Shares). Contributed Surplus at June 30, 2019 is $811,407 (June 30, 2018 – $699,397) the increase is the result of the share-based payments recognized for the year. As a result of the net loss for the quarter ending June 30, 2019 of $120,557 (June 30, 2018 – $110,911) the deficit at June 30, 2019 increased to $6,401,698 from $5,845,440 as at June 30, 2019.

At present, the Company's operations do not generate cash inflows and its financial success after June 30, 2019 is dependent on management's ability to continue to obtain sufficient funding to sustain operations through the development stage and successfully bring the Company's technologies to the point that they may be out licensed so that the Company achieves profitable operations. The research and development process can take many years and is subject to factors that are beyond the Company's control.

In order to finance the Company's future research and development and to cover administrative and overhead expenses in the coming years the Company may raise money through equity sales. Many factors influence the Company's ability to raise funds, including the Company's record of accomplishment, and the experience and caliber of its management. Actual funding requirements may vary from those planned due to various factors, including the progress of research activities. Management believes it will be able to raise equity capital as required in the long term but recognizes there will be risks involved that may be beyond their control. Should those risks fully materialize, it may not be able to raise adequate funds to continue its operations.

Since the Company will not be able to generate cash from its operations in the foreseeable future, the Company will have to rely on funding through future equity issuances and through short term borrowing in order to finance ongoing operations. The ability of the Company to raise capital will depend on market conditions and it may not be possible for the Company to issue shares on acceptable terms or at all. See subsequent event for additional information.

1.7 Capital Resources

The Company does not have any other commitments for material capital expenditures. The Company is not a party to any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on the Company's financial condition, changes in financial condition, revenues, expenses, results of operations, liquidity, capital expenditures or capital resources.

1.8 Off-Balance Sheet Arrangements

There is no off-balance sheet arrangements to which the Company is committed.

1.9 Transactions Between Related Parties

During the quarter ended June 30, 2019, the Company entered into the following transactions with related parties:

a) For the quarter ended June 30, 2019, directors and officers of the company provided consulting services to the company of $82,500. These charges are included in consulting fees. Consulting fees from the CEO was $60,000 and the Interim CFO also performing duties as the Project Director was $22,500 for the quarter ended June 30, 2019. As at June 30, 2019, The Company has $646,946 due to CEO (2018 - $579,946). The balance owing to the interim CFO as at June 30, 2019 is $119,145 (2018 - $112,645). The balances due to related parties are unsecured, non-interest bearing and without fixed repayment terms.

b) For the quarter ended June 30, 2019, the Company recognized $nil of share-based compensation for stock options held by director and officers.

c) On May 14, 2014, the Company entered a General Service Agreement (the "Service Agreement") with BioMark Technologies Inc., Both Biomark Diagnostics and BioMark Technologies are managed by the CEO of the Company. According to the Service Agreement, the Company engaged Biomark Technologies to provide important services that include continuation of research and development, establishing a framework quality management system, IP refinement and filing, establish protocols with key investigators, linking platforms that BioMark Diagnostics can

leverage, engage in territorial business development from relationships that Biomark Technologies developed over the years, supplier validation and review, operating capital and other related functions (the "Services"). Biomark Technologies uses subcontractors to perform some of its services. The Company will pay management fees equivalent to cost plus a 25% administration fee to Biomark Technologies and payable upon completion of the Services. For the quarter ended June 30, 2019, the Company paid $nil to Biomark Technologies as administration fees (2018 - $nil). BTI holds approximately 60% of the common shares of the Company as at June 30, 2019 (2018 – 65%). The CEO owns more than 10% interest in the Company. The term of this Agreement will remain in full force and effect indefinitely until terminated as provided in the Agreement. In the event that either party wishes to terminate this Agreement, that each party will be required to provide 30 days' notice to the other party.

d) On May 14, 2014, the Company entered into an Independent Contractor Agreement (the "Agreement") with the CEO of the Company. According to the Agreement, the CEO will provide consulting services to the Company for one year with a compensation of $240,000 per year plus benefits. In addition, the CEO will be paid a cash bonus equivalent to 30% of the annual salary at the end of each year if the trading price of the Company shares increased by more than 30% from the trading price at the beginning of the year. For the purpose of this calculation, the starting trading price is $0.25 per share. The CEO will also be granted stock options for 1,000,000 shares at a price of $0.25 per share (granted). Finally, if the Company's market capitalization exceeds $200 million USD, the CEO will be paid an additional cash bonus of $500,000. The terms of the CEO agreement are on year to year basis unless terminated accordance to the terms and conditions set forth in the agreement. According to the Agreement, the Company engaged CEO service to provide important services that include develop and direct the corporate strategy, resource allocation, review acquisitions or partnerships, drive or generate revenue growth, hire, and retain staff as necessary, support in capital raise rounds, manage past relationships and build business and collaborations.

1.10 Fourth Quarter

N/A

1.11 Proposed Transactions

N/A

1.12 Critical Accounting Estimates

The preparation of the consolidated financial statements in accordance with IFRS requires the Company to make estimates and assumptions concerning the future. The Company's management reviews these estimates and underlying assumptions on an ongoing basis, based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to estimates are adjusted for prospectively in the period in which the estimates are revised. However, actual outcomes can differ from these estimates. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The more significant areas are as follows:

- the estimates and assumptions used in the share-based payments; and
- the fair value measurements for financial instruments;

The preparation of consolidated financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. Actual results may differ from these estimates.

Significant areas where management's judgment has been applied include:

- Classifying categories of financial assets and financial liabilities in accordance with IAS 39, Financial instruments: recognition and measurement;
- Evaluating if the criteria for recognition of provisions and contingencies are met in accordance with IAS 37, Provisions, contingent liabilities and contingent assets; and
- The assessment of the Company's ability to continue as a going concern.

1.13 Changes in Accounting Policies including Initial Adoption

New accounting standards adopted effective April 1, 2018

IFRS 9 Financial Instruments
IFRS 9, "Financial Instruments" replaced IAS 39, "Financial Instruments: Recognition and Measurement" ("IAS 39") and all previous versions of IFRS 9. The Company elected to apply IFRS 9 using a full retrospective approach. IFRS 9 replaces the provisions of IAS 39 that relate to the recognition, classification, and measurements of financial assets and financial liabilities, derecognition of financial instruments and impairment of financial assets. IFRS 9 uses a single approach to determine whether a financial asset is classified and measured at amortized cost or fair value. The approach in IFRS 9 is based on how the Company manages its financial instruments and the contractual cash flow characteristics of the financial asset. Most of the requirements in IAS 39

for classification and measurement of financial liabilities were carried forward in IFRS 9. The application of IFRS 9 did not impact the Company's classification and measurement of financial assets and liabilities, and there was also no impact to the carrying value of any of the Company's financial assets or liabilities on the date of transition.

New accounting standards issued but not yet effective

Certain new standards, interpretations, amendments and improvements to existing standards were issued by the IASB or IFRIC that are mandatory for future accounting periods. The following have not yet been adopted by the Company and are being evaluated to determine their impact.

- IFRS 16: Leases: New standard to establish principles for recognition, measurement, presentation and disclosure of leases with an impact on lessee accounting, effective for annual periods beginning on or after January 1, 2019.

Based on current expectations, the Company does not expect these standards to have a significant impact on the financial statements.

1.14 Financial Instruments and Other Instruments

Fair values

The Company's financial instruments include cash, accounts payable and due to related parties. The carrying amounts of these financial instruments are a reasonable estimate of their fair values because of their current nature.

The Company classifies its fair value measurements in accordance with an established hierarchy that prioritizes the inputs in valuation techniques used to measure fair value as follows:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 – Inputs that are not based on observable market date.

Credit risk

The Company is not exposed to credit risk.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Financial assets and liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates, but it does not believe it is currently subject to any significant interest rate risk.

Liquidity risk

The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments.

The Company intends to meet its current obligations in the following year with funds to be raised through private placements, shares for debt, loans and related party loans.

1.15 Other MD&A Requirements

(a) More information about the Company is on SEDAR at www.sedar.com.

(b) Information required in the following sections of National Instrument 51-102, if applicable:

(i) Section 5.3 – Additional Disclosure for Venture Issuers without Significant Revenue;

An analysis of material components of the Company's general and administrative expenses is disclosed in the Statement of Comprehensive Loss forming part of the Financial Statements for the period ended June 30, 2019 to which this MD&A relates.

(ii) Section 5.4 – Disclosure of Outstanding Share Data; and

a. Authorized:

Unlimited common shares without par value

b. Common Shares Issued:

As at June 30, 2019, the Company had 69,145,410 common shares issued and outstanding.

On April 16th, 2019, the Issuer issued 2,000,000 units at a price of CAD $0.10 per unit for gross proceeds of $ 200,000. Each unit consists of one common share of the Issuer and one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of the Issuer at $0.20 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause.

On June 18th, 2019, pursuant to the Debt Settlement that BioMark Diagnostics announced, the Company issued a total of 1,000,000 shares (the "Debt Shares") to director and officer at deemed price of $0.15 per Debt Share in settlement of the indebtedness in aggregate amount of $150,000. No warrants were issued in connection with the debt settlement. The Debt Shares will be subject to a four month plus 1-day hold period.

As of June 29th, 2019, 1,130,291 shares have been issued upon the exercise of the warrants by the warrant holders at a price of $0.15 per share (the "Exercise Price"), upon and subject to the terms and conditions.

c. Share Purchase Warrants

As at June 30, 2019, the Company had 4,027,664 shareholder warrants issued and outstanding of which 2,027,664 warrant will entitle the holder to acquire one share at a price of $0.15 per share and 2,000,000 warrants will entitle the holder to acquire one share at price of $0.20 per share for a period of two years after its Closing Date respectively. The Company uses the residual value method to allocate proceeds of the unit amongst the common share and the share purchase warrant.

d. Stock options:

The Company has reserved 4,675,000 common shares under its Existing Plan. The plan provides for the granting of options to directors, employees, and consultants. Stock options granted generally have varying expiry terms of up to five years and vesting periods determined at the discretion of the directors.

The number of options exercisable as at June 30, 2019 was 4,675,000 (2018 – 4,125,000 options). The weighted average life remaining for these options was 0.68 years and weighted average exercise price was $0.22 per option.

(iii) Section 5.7 – Additional Disclosure for Reporting Issuers with Significant Equity Investees.

Not Applicable.

(c) Disclosure required by National Instrument 52-109 *Certification of Disclosure in Issuers' Annual and Interim Filings* and, as applicable, Form 52-109F1 *Certification of Annual Filings – Full Certificate*, Form 52-109F1R *Certification of Refiled Annual Filings*, or Form 52-109F1 *AIF Certification of Annual Filings in Connection with Voluntarily Filed AIF*.

Form 52-109FV2 Certification of Interim Filings is filed on SEDAR.